BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30797014)

  • 1. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
    Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
    Patel M; McSorley ST; Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC
    Br J Cancer; 2018 Mar; 118(5):705-712. PubMed ID: 29337962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
    Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J
    Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
    Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
    Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
    Rosati G; Lonardi S; Galli F; Di Bartolomeo M; Ronzoni M; Zampino MG; Banzi M; Zaniboni A; Pasini F; Bozzarelli S; Garattini SK; Ferrari D; Montesarchio V; Mambrini A; Ciuffreda L; Galli F; Pusceddu V; Carlomagno C; Bidoli P; Amoroso D; Bochicchio AM; Frassineti L; Corsi D; Bilancia D; Pastorino A; De Stefano A; Labianca R;
    Eur J Cancer; 2021 May; 148():190-201. PubMed ID: 33744715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
    Hubbard J; Thomas DM; Yothers G; Green E; Blanke C; O'Connell MJ; Labianca R; Shi Q; Bleyer A; de Gramont A; Sargent D
    J Clin Oncol; 2012 Jul; 30(19):2334-9. PubMed ID: 22614981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
    Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
    J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
    Sinicrope FA; Foster NR; Yothers G; Benson A; Seitz JF; Labianca R; Goldberg RM; Degramont A; O'Connell MJ; Sargent DJ;
    Cancer; 2013 Apr; 119(8):1528-36. PubMed ID: 23310947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
    Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE
    Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
    Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
    Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower survival after right-sided versus left-sided colon cancers: Is an extended lymphadenectomy the answer?
    Lee L; Erkan A; Alhassan N; Kelly JJ; Nassif GJ; Albert MR; Rt Monson J
    Surg Oncol; 2018 Sep; 27(3):449-455. PubMed ID: 30217301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.